Colchicine for Diabetic Nephropathy Trial (CDNT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02442921|
Recruitment Status : Recruiting
First Posted : May 13, 2015
Last Update Posted : May 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathies||Drug: Colchicine Drug: Placebo||Phase 1 Phase 2|
Diabetic nephropathy is the leading cause today for end stage renal failure in the western world. Multifactorial intervention in patients may slow the rate of albuminuria and renal injury; however several new drug trials have failed so far to significantly attenuate its progression. Several pathways are identified in the development of diabetic nephropathy, however, in recent years many researchers suspect that inflammatory pathways play central roles in the progression of diabetic neuropathy . There is compelling evidence that diabetes mellitus has an auto-inflammatory component with Nlrp3 inflammasome and interleukin -1 β activation. Colchicine is a relatively safe anti-inflammatory drug used to treat and reverse albuminuria in familial Mediterranean fever nephropathy, an auto-inflammatory disease. Data from one study demonstrated that colchicine diminished proteinuria and inflammation in experimental-diabetic animal models.
Working hypothesis and aims:
To assess whether colchicine reduces proteinuria in diabetic patients with diabetic neuropathy , despite maximal multi-factorial interventions (angiotensin-converting-enzyme inhibitors, tight glycemic and hypertensive control, lifestyle intervention, etc.).
Forty patients with stable diabetes, and diabetic neuropathy with proteinuria of 0.5-6g/24 hours, despite standard treatment, will receive colchicine (n=20) or placebo (n=20) for 18 months. Urinary protein and creatinine clearance will be assessed three months before the study initiation, at baseline and every three months thereafter. Blood creatinine, complete blood count, creatine phosphokinase , liver function tests, fasting Glucose Test, HbA1c, and urine protein/creatinine ratio and diabetes mellitus treatment monitoring and follow-up will be performed every three months. Oral colchicine treatment will be initiated at 1mg per day, and increased gradually to 2 mg, if gastrointestinal or musculoskeletal disturbances are absent or tolerated. The participants will be called and evaluated a year after the end of treatment for all parameters mentioned. Statistical analysis will be performed by a statistician.
A significant reduction or stabilization of proteinuria during the 18 month treatment period, or at follow up at one year later.
Importance and Relevance to the call This study may define a new treatment for diabetic nephropathy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||The Effect of Colchicine Treatment on the Progression of Proteinuria in Patients With Diabetic Nephropathy.|
|Actual Study Start Date :||February 22, 2016|
|Estimated Primary Completion Date :||April 30, 2019|
|Estimated Study Completion Date :||April 30, 2019|
20 patients will receive up to 2 mg of colchicine for 18 months
up to 2mg of Colchicine daily
Placebo Comparator: Placebo
20 patients will receive placebo for 18 months
- Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months. [ Time Frame: From baseline to 18 months ( end of trial ) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442921
|Contact: Shaye Kivity, MDfirstname.lastname@example.org|
|Contact: Naomi Friedman, Ms.email@example.com|
|Sheba Medical Center||Recruiting|
|Ramat Gan, Israel, 52621|
|Contact: Shaye Kivity, MD 0526668134 firstname.lastname@example.org|
|Contact: Naomi Friedman, M.sc +972544451556 email@example.com|
|Principal Investigator:||Shaye Kivity, MD||Sheba Medical Center|